Education
About Us
Working with TipRanks
Follow Us
Eupraxia Pharmaceuticals (TSE:EPRX)
TSX:EPRX
EPRX Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$3.07 - C$8.13
Previous CloseN/A
Volume2.50K
Average Volume (3M)28.96K
Market Cap
C$269.17M
Enterprise ValueC$295.74M
Total Cash (Recent Filing)C$27.45M
Total Debt (Recent Filing)C$52.77K
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Nov 05, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding35,959,568
10 Day Avg. Volume32,782
30 Day Avg. Volume28,965
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$14.33Price Target Upside94.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Efficacy And SafetyEP-104GI demonstrated a favorable safety profile, with no serious adverse events reported and plasma fluticasone levels remaining low and consistent.
Market OpportunityEupraxia has the potential for a best-in-class treatment for the ever-growing eosinophilic esophagitis (EoE) market, and has shown the potential for an annual treatment of EP-104GI in this condition, which could grow to a ~1M addressable patient market.
Product PotentialEP-104GI could be dosed annually, and be a much more valuable product than the current EPRX stock reflects.
Bears Say
Financial PerformanceFor Q2 2025, Eupraxia reported a net loss of $8.7M versus $6.1M in Q2 2024, driven by higher R&D and G&A expenses.
Eupraxia Pharmaceuticals News
EPRX FAQ
What was Eupraxia Pharmaceuticals’s price range in the past 12 months?
Eupraxia Pharmaceuticals lowest stock price was C$3.07 and its highest was C$8.13 in the past 12 months.
What is Eupraxia Pharmaceuticals’s market cap?
Eupraxia Pharmaceuticals’s market cap is C$269.17M.
When is Eupraxia Pharmaceuticals’s upcoming earnings report date?
Eupraxia Pharmaceuticals’s upcoming earnings report date is Nov 05, 2025 which is in 56 days.
How were Eupraxia Pharmaceuticals’s earnings last quarter?
Eupraxia Pharmaceuticals released its earnings results on Aug 12, 2025. The company reported -C$0.333 earnings per share for the quarter, missing the consensus estimate of -C$0.256 by -C$0.077.
Is Eupraxia Pharmaceuticals overvalued?
According to Wall Street analysts Eupraxia Pharmaceuticals’s price is currently Undervalued.
Does Eupraxia Pharmaceuticals pay dividends?
Eupraxia Pharmaceuticals does not currently pay dividends.
What is Eupraxia Pharmaceuticals’s EPS estimate?
Eupraxia Pharmaceuticals’s EPS estimate is -0.29.
How many shares outstanding does Eupraxia Pharmaceuticals have?
Eupraxia Pharmaceuticals has 35,959,568 shares outstanding.
What happened to Eupraxia Pharmaceuticals’s price movement after its last earnings report?
Eupraxia Pharmaceuticals reported an EPS of -C$0.333 in its last earnings report, missing expectations of -C$0.256. Following the earnings report the stock price went up 0.537%.
Which hedge fund is a major shareholder of Eupraxia Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:EPRX
Eupraxia Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$14.33 (94.97% Upside)
C$14.33 (94.97% Upside)
Insider Transactions
Bought Shares
Worth C$83.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
117.45%
12-Months-Change
Fundamentals
Return on Equity
-158.24%
Trailing 12-Months
Asset Growth
-5.79%
Trailing 12-Months
Company Description
Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
EPRX Stock 12 Month Forecast
Average Price Target
C$14.33
▲(94.97% Upside)
Technical Analysis
Arch Biopartners
―
Medicenna Therapeutics Corp
―
Fennec Pharmaceuticals
―
NervGen Pharma
―
Bright Minds Biosciences
―
Options Prices
Currently, No data available
---